|
|
|
European Pharmaceutical Contractor
|
| Reducing drug supply costs and managing risk are realistic goals, asserts Wade Wirta of Perceptive Informatics, through the use of IVRS to integrate clinical and supply chain data
Interactive voice response systems (IVRS) have been available for many years to help clinical trial sponsors improve the efficiency and accuracy of patient enrolment, randomisation, drug inventory management and trial data collection. Yet despite the demonstrated benefits of IVRS, only about 30 per cent of clinical trials conducted today are making use of this technology, or the more recently introduced interactive web-based response systems (IWRS), to manage these mission-critical functions (IVRS will refer to both IVR and IWR for the remainder of this article). Given the intense competition and rising trial costs in the bio/pharmaceutical industry, it is more important than ever for trial sponss to understand the advantages of IVRS and leverage this technology to control costs, manage risk and streamline clinical trial processes.
One of the key trial functions for which IVRS helps reduce both cost and risk is drug supply inventory management. With the increasingly global scope of clinical trials and the high cost of many complex new drugs entering development, the ability to efficiently manage the supply chain is vital to the success of most clinical trials. By proactively managing drug supplies through an IVRS, sponsors create a seamless supply chain, allowing stakeholders in the clinical trial process to track and manage critical drug supply inventory throughout the lifecycle of a study. Utilising this technology to enable just-in-time (JIT) inventory deliveries and to integrate sophisticated drug supply forecasting techniques, sponsors can reduce costly drug supply overproduction and overstocking; decrease the risk and expense associated with expired inventory; and prevent drug supply shortfalls that could jeopardise a trial. |
Read full article from PDF >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|

 |
Industry Events |
 |
BioPartnering North America™
26-28 February 2012, Vancouver Convention Centre, Vancouver, BC, Canada
BioPartnering North America 2012 (BPN) in Vancouver, Canada brings together senior executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size from mature to start-up.
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|